AI Cuts Drug Development Costs by 70%, Survey Finds

Artificial intelligence is fundamentally reshaping how pharmaceutical companies approach early-stage drug development, with new survey data revealing cost and timeline reductions of up to 70% in preclinical research phases.

A proprietary TD Cowen survey of 80 biopharma leaders and industry insiders shows the technology is driving a major automation push that could add more than 10% to new drug development programs over the next three to five years, according to details first reported by Axios.

Why it matters

The dramatic efficiency gains are prompting pharmaceutical companies to redirect resources toward advanced computational tools and modeling platforms, potentially enabling researchers to test thousands more experimental compounds. This shift could increase the volume of treatments entering clinical trials — though success rates remain uncertain.

The automation wave

The survey findings indicate that technology investments, combined with expanded laboratory capacity, could generate an additional $1 billion in incremental spending across the industry. Demand is strongest for software that can simulate biological processes, predict drug interactions, and model dosing requirements for specific populations including newborns and pregnant women.

Companies are already investing heavily in "in silico" platforms — computational tools that allow scientists to run thousands of virtual experiments in seconds and evaluate a compound's toxicity or stability before physical testing begins.

"The hope is to 'create more shots on goal,'" says Brendan Smith, director of life sciences equity research at TD Cowen, referring to the ability to generate large datasets that train AI models to improve clinical success probabilities.

The laboratory evolution

While AI cannot replace scientific intuition, its ability to streamline research before human trials begin is making computational screens as central to drug design as traditional wet labs. Scientists will still evaluate compound safety and effectiveness in physical laboratories, but the workflow is shifting toward a continuous research loop between digital and physical experimentation.

The Trump administration's efforts to reduce animal testing in biomedical research are accelerating this transition, pushing more work toward computational tools, 3D human tissue models, and other alternatives for predicting compound toxicity.

Persistent challenges

No AI-discovered drug has yet won Food and Drug Administration approval, and investor skepticism remains about the technology's ultimate impact on patient outcomes. Critics worry that computational optimization may inadequately account for human biological variation before compounds reach clinical trials, potentially leaving the drug failure rate near its current 90% level.

Additional concerns include China's biotech expansion, which continues to attract billions in investment by offering lower costs and faster turnaround times. Meanwhile, the administration's evolving AI policy approach — attempting to balance light regulation with safety and privacy oversight — creates uncertainty for long-term research planning.

These findings were first reported by Axios, drawing on TD Cowen's proprietary survey data.